Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0DG9F
|
|||
| Former ID |
DIB014246
|
|||
| Drug Name |
PP-1420
|
|||
| Synonyms |
Pancreatic polypeptide analog (sc, obesity), Imperial College London
Click to Show/Hide
|
|||
| Indication | Obesity [ICD-11: 5B81; ICD-10: E66; ICD-9: 278] | Phase 1/2 | [1] | |
| Company |
Imperial College London
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Pancreatic hormone (PH) | Target Info | Modulator | [2] |
| Reactome | Peptide ligand-binding receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | GPCR ligand binding | |||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02221765) Safety, Tolerability and Efficacy Study of PP1420 in HV. U.S. National Institutes of Health. | |||
| REF 2 | Pharmacokinetics, adverse effects and tolerability of a novel analogue of human pancreatic polypeptide, PP 1420. Br J Clin Pharmacol. 2012 Feb;73(2):232-9. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.